Peter Hunt

USPTO Granted Patents = 16 (Patent Applications = 5)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 7 (Patent Applications = 2)

Average Co-Inventor Count = 6.1

ph-index = 3

Forward Citations = 47(Granted Patents)

Location History:

Storrington, GB (2012 - 2016)
Horsham, GB (2011 - 2017)

Company Filing History:

Corcept Therapeutics Incorporated

patents

Years Active: 2011-2024

Loading Chart...

16 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12098141 - Bicyclic indazole glucocorticoid receptor antagonists (2024-09-24),

2. 9643983 - Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives (2017-05-09),

3. 9522149 - Pyrazine derivatives as ENaC blockers (2016-12-20),

4. 9139586 - Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives (2015-09-22),

5. 9115087 - Squaramide derivatives as CXCR2 antagonist (2015-08-25),

6. 9050339 - Pyrazine derivatives as ENaC blockers (2015-06-09),

7. 8722925 - Squaramide derivatives as CXCR2 antagonist (2014-05-13),

8. 8697687 - Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives (2014-04-15),

9. 8431578 - Organic compounds (2013-04-30),

10. 8372845 - Pyrazine derivatives as enac blockers (2013-02-12),

11. 8343966 - Organic compounds (2013-01-01),

12. 8329754 - Squaramide derivatives as CXCR2 antagonist (2012-12-11),

13. 8288588 - Squaramide derivatives as CXCR2 antagonist (2012-10-16),

14. 8236808 - Pyrazine derivatives as ENAC blockers (2012-08-07),

15. 8039472 - Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel (2011-10-18),

Title: The Innovative Mind of Peter Hunt: A Glimpse into His Contributions

Introduction: Peter Hunt, an accomplished inventor based in West Sussex, GB, has made significant strides in the field of pharmaceuticals. With one patent to his name, he has showcased his expertise through the development of compounds that target glucocorticoid receptors. His work at Corcept Therapeutics Incorporated has positioned him as a notable figure in the innovation landscape.

Latest Patents: Peter Hunt holds a patent for "Bicyclic indazole glucocorticoid receptor antagonists." This patent encompasses compounds of Formula I, Ia, Ib, Ib-1, Ib-2, Ic, Ic-1, Id-1, and Id-2. These compounds are valuable in pharmaceutical formulations aimed at modulating glucocorticoid receptors, highlighting the potential therapeutic applications of his research.

Career Highlights: Throughout his career, Peter has demonstrated a commitment to advancing scientific knowledge and innovation. His role at Corcept Therapeutics Incorporated emphasizes his dedication to developing new solutions within the pharmaceutical field.

Collaborations: Peter Hunt has collaborated with talented coworkers, including Lorna Duffy and Thomas Hornsby. These partnerships have undoubtedly contributed to the success and effectiveness of their initiatives in pharmaceutical research and development.

Conclusion: Peter Hunt exemplifies the spirit of innovation through his contributions to the pharmaceutical industry. With his patent showcasing significant advancements, his work is set to impact the future of glucocorticoid receptor modulation. As part of a dedicated team at Corcept Therapeutics Incorporated, his collaborations and research continue to inspire new possibilities in medicine.

This text is generated by artificial intelligence and may not be accurate.